PF-00489791

DB11736InvestigationalSmall molecule

PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.

Mechanism: Pharmacologically active on cGMP-specific 3',5'-cyclic phosphodiesterase
Curator reviewed
Formula / weight: C₂₀H₂₈N₈O₄S · 476.56 g/mol (avg)
Code names: PF-489,791 · UK-489,791

Resolves to

Compound

UNII2S27T3DSZ3CAS853003-48-2PubChem11465695

Structure

InChIKeyZUHZNKJIJDAJFD-UHFFFAOYSA-NSMILESCCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC

Targets

O76074PDE5A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-00489791, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account